GeneSign Biotech (Xiamen)Co., Ltd.

GeneSign Biotech (Xiamen) specializes in in vitro diagnostic (IVD) tests, including rapid antigen detection devices and fluorescence immunoassays (FIA). Their portfolio covers point-of-care diagnostics for infectious diseases (e.g., COVID-19, RSV, adenovirus, malaria), cardiac markers (like troponin), allergens (IgE), and inflammatory biomarkers (CRP, PCT). These tests are designed for quick, on-site screening or laboratory analysis, often enabling multi-pathogen detection in a single device.

GeneSign Biotech (Xiamen) is headquartered in China. As a manufacturer supplying the European market, its devices must comply with EU regulatory requirements for IVDs, including registration in EUDAMED (the EU’s medical device database). While the company’s location influences supply chain and manufacturing standards, individual devices—such as rapid tests or immunoassays—must meet EU’s IVD General classification criteria for market authorization.

Yes, GeneSign Biotech’s IVD devices are registered in EUDAMED, the official EU database for medical devices. This listing confirms their presence in the European market and provides transparency on regulatory status. Since all listed devices fall under the IVD General classification, they undergo risk assessments and conformity evaluations to ensure safety and performance before authorization, which is critical for healthcare providers and regulators.

GeneSign Biotech’s devices are classified under the EU IVD General category, meaning they are not high-risk (e.g., not Class C or D). This classification applies to tests like rapid antigen tests or immunoassays for infectious diseases or biomarkers. Under EU regulations, such devices still require conformity assessment (e.g., technical documentation, risk management) to demonstrate safety and performance, but the process is less stringent than for higher-risk IVDs. The classification ensures balanced oversight while facilitating accessibility for point-of-care diagnostics.